KR101528265B1 - Cosmetic Composition for Reducing Skin Wrinkle Comprising beta-Lapachone - Google Patents
Cosmetic Composition for Reducing Skin Wrinkle Comprising beta-Lapachone Download PDFInfo
- Publication number
- KR101528265B1 KR101528265B1 KR1020100035204A KR20100035204A KR101528265B1 KR 101528265 B1 KR101528265 B1 KR 101528265B1 KR 1020100035204 A KR1020100035204 A KR 1020100035204A KR 20100035204 A KR20100035204 A KR 20100035204A KR 101528265 B1 KR101528265 B1 KR 101528265B1
- Authority
- KR
- South Korea
- Prior art keywords
- beta
- composition
- skin
- rapacon
- cream
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 230000037303 wrinkles Effects 0.000 title claims abstract description 29
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 title description 19
- 108010035532 Collagen Proteins 0.000 claims abstract description 16
- 102000008186 Collagen Human genes 0.000 claims abstract description 16
- 229920001436 collagen Polymers 0.000 claims abstract description 15
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 8
- 239000006071 cream Substances 0.000 claims description 44
- 238000009472 formulation Methods 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 21
- 239000006210 lotion Substances 0.000 claims description 12
- -1 serum Substances 0.000 claims description 12
- 230000006872 improvement Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 6
- 239000000686 essence Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000008234 soft water Substances 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000002585 base Substances 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 230000000475 sunscreen effect Effects 0.000 claims 1
- 230000036570 collagen biosynthesis Effects 0.000 abstract description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 53
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 27
- 229960003471 retinol Drugs 0.000 description 27
- 235000020944 retinol Nutrition 0.000 description 27
- 239000011607 retinol Substances 0.000 description 27
- 210000003491 skin Anatomy 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 206010040880 Skin irritation Diseases 0.000 description 12
- 231100000475 skin irritation Toxicity 0.000 description 12
- 230000036556 skin irritation Effects 0.000 description 12
- 238000007796 conventional method Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 231100000430 skin reaction Toxicity 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 102000016942 Elastin Human genes 0.000 description 8
- 108010014258 Elastin Proteins 0.000 description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 229920002549 elastin Polymers 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000037319 collagen production Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 201000000582 Retinoblastoma Diseases 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229940079894 benzophenone-9 Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 229950011392 sorbitan stearate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 241001090347 Bignoniaceae Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241000219071 Malvaceae Species 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 241000013557 Plantaginaceae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000208465 Proteaceae Species 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241001073567 Verbenaceae Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000220217 Sapotaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241001530102 Tabebuia Species 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 베타-라파콘을 유효성분으로 하는 콜라겐 생합성 촉진용 피부 외용제 조성물 및 화장료 조성물에 관한 것으로, 상기 조성물은 콜라겐 합성을 촉진함으로써, 피부 주름을 보다 완화시킬 수 있고 하고, 견고하며 탄력있게 유지해주The present invention relates to a composition for external application for skin for promoting collagen biosynthesis and a cosmetic composition comprising beta-raffone as an active ingredient. The composition is capable of alleviating skin wrinkles by promoting collagen synthesis, Huh
Description
본 발명은 베타-라파콘을 포함하는 콜라겐 생성 촉진용 피부 외용제 조성물 및 화장료 조성물에 관한 것이다.The present invention Beta-rapacon, and a cosmetic composition for accelerating collagen production.
피부는 체내의 근육들과 기관을 보호하는 다수의 상피조직으로 이루어진 외피 체계에서 가장 큰 조직으로, 외부 환경으로부터 신체 내부를 보호하여 체내의 항상성을 유지시키는데 중요한 역할을 한다. 그 결과 피부는 외부에서 주어지는 물리적, 화학적 자극, 스트레스, 영양 결핍 등에 의해 피부의 정상기능이 저하되고 탄력 저하, 주름 생성 등의 피부 노화 현상이 촉진된다.Skin is the largest tissue in the epidermal system consisting of multiple epithelial tissues that protects the muscles and organs in the body and plays an important role in maintaining the body's homeostasis by protecting the inside of the body from the external environment. As a result, the skin is exposed to external physical and chemical stimuli, stress, nutritional deficiencies, such as the normal function of the skin degraded, elasticity and wrinkles, such as skin aging phenomenon is promoted.
피부의 노화는 내인적 노화(innate age)와 외인적 노화(extrinsic age)로 구분할 수 있다. 상기 내인적 노화는 연령이 증가함에 따라 발생하는 노화로, 신체의 생리적인 기능이 저하되어 나타나는 노화이다. 또한, 상기 외인적 노화는 외부 자외선, 활성산소, 스트레스 등에 의해 발생하는 노화 현상을 말한다. 이러한 내인적 및 외인적 노화 요인에 의해 피부의 노화가 진행되고, 그 결과 피부 표면에 주름이 생성되어 피부결이 거칠어지고 탄력이 감소한다.Skin aging can be divided into innate age and extrinsic age. The above-mentioned internal aging is an aging caused by an increase in age, and aging resulting from a decrease in the physiological function of the body. The external aging refers to the aging phenomenon caused by external ultraviolet rays, active oxygen, stress, and the like. These internal and external aging factors aging the skin promote wrinkles on the skin surface, resulting in rough skin texture and reduced elasticity.
주름이 생성되는 기작에 따르면, 진피 내의 콜라겐(collagen), 엘라스틴(elastin) 등은 분해 및 생성이 계속해서 이루어지는데, 이때 분해작용 후 생성작용으로 인한 보충이 원활하지 않으면 피부가 탄력을 잃고 주름이 생성된다.According to the mechanism of wrinkle formation, the collagen (collagen) and elastin in the dermis continue to be decomposed and produced. If the supplement after the decomposition is not smooth, the skin loses elasticity and wrinkles .
지금까지 연구보고된 대표적인 주름완화 및 피부 노화 예방 물질로는 레티노익산(retinoic acid), 레티놀(retinol), 아스코르브산(ascorbic acid), α-히드록시산(α-hydroxy acid) 등이 있다. Retinoic acid, retinol, ascorbic acid, and? -Hydroxy acid are among the representative anti-wrinkle and anti-aging substances reported so far.
레티노익산은 지질과산화(lipid per-oxidation) 및 오르니틴 디카복실라아제 반응(ornithine decarboxylase response)을 억제한다. 그러나 자외선에 의해 민감한 반응을 보이며 자극이 높아 피부가 붉어지는 부작용이 보고되어 사용이 제한되고 있으며, 또한, 6개월 이상 계속 사용해야만 효과가 나타나는 문제점이 있다. Retinoic acid inhibits lipid per-oxidation and ornithine decarboxylase response. However, it is sensitive to ultraviolet rays and has a high irritation, so it has been reported that side effects of redness of the skin have been reported, and its use is restricted.
레티놀은 레티노익산에 비해 주름개선 효과가 약하지만 상대적으로 안전성이 높아 널리 사용되고 있다. 그러나 레티놀을 고농도로 사용하면 피부자극이 발생하며, 자외선에 노출 시 피부 색소 침착을 일으키며, 공기 중의 산소, 열 및 빛 등에 의해 쉽게 산화되므로 안정성에 문제가 있다. Retinol is less effective for wrinkle improvement than retinoic acid, but is widely used because of its relatively high safety. However, when retinol is used at a high concentration, skin irritation occurs, skin pigmentation occurs upon exposure to ultraviolet rays, and oxidation is easily caused by oxygen, heat and light in the air.
아스코르브산은 공기, 수분, 고온 등 외부 환경에 의해 쉽게 산화되어 그에 따라 활성이 많이 감소하므로 주름개선 정도가 낮아지고, 제형의 변색 및 변취를 유발하는 문제점이 있다.Ascorbic acid is easily oxidized by the external environment such as air, water, and high temperature, and thus the activity is greatly reduced, thereby lowering the degree of wrinkle improvement and causing discoloration and deterioration of the formulation.
또한, α-히드록시산도 항주름제로 공시되어 있으나, 가려움, 홍반, 자외선에 민감성 반응 등 피부자극 부작용이 수반되어 제품의 안전성 측면에 문제점이 있다. Although α-hydroxy acid is also disclosed as an anti-wrinkle agent, there are side effects of skin irritation such as itching, erythema, and sensitivity to ultraviolet rays, thereby causing a problem of safety of the product.
이외에도, 주름 방지를 위해 자외선 차단제, 보습제, 항산화제 등을 함유한 화장품들이 널리 사용되고 있으나 이 제품들의 실질적인 주름 개선 효과는 미미한 편이다.In addition, cosmetic products containing sunscreen agents, moisturizers, and antioxidants are widely used to prevent wrinkles, but the effect of wrinkles on these products is minimal.
본 발명자들은 여러 화합물을 스크리닝하던 중 베타-라파콘이 콜라겐 생성을 촉진하는 효과를 확인하여 피부 외용제를 비롯 화장료 조성물에 적용하기 위한 연구를 진행하였다.The present inventors confirmed the effect of promoting the production of collagen by beta-raffone during the screening of various compounds and proceeded to apply them to cosmetic compositions including external preparations for skin.
베타-라파콘(lapachol)은 라파초 트리(lapacho tree, Tabebuia avellandedae,)로부터 얻어지는 천연 퀴논 물질로서, 다양한 식물로부터 추출된다.Beta-lapachol is a lapacho tree ( Tabebuia avellandedae , which is extracted from various plants.
종래 연구를 통해 베타-라파콘이 항암 효과[Terai, Kaoru et al., Cisplatin enhances the anticancer effect of beta - lapachone by upregulating NQO1. , Anticancer Drugs,Nov,01;20(10):901-9 (2009); 미합중국특허 제7,074,824호, 제6,962,944호, 제6,664,288호, 제7,361,691호, 국제특허공개 WO 2003/11224호], 항종양 효과[H R Shah et al., Beta - lapachone inhibits proliferation and induces apoptosis in retinoblastoma cell linesBeta - lapachone in retinoblastoma cell lines, Eye 22, 454-460 (March 2008); 미합중국 특허공개 제2009/0226395호, 제7,070,797호], 항염증 효과[Dong-Oh Moon et al., Anti-inflammatory effects of β- lapachone in lipopolysaccharide - stimulated BV2 microglia, International Immunopharmacology, Vol 7, Issue 4, 506-514, (April 2007)], 항진균 효과[Shing-Hwa Liu et al., Inhibition of inducible nitric oxide synthase by β-lapachone in rat alveolar macrophages and aorta, Br J Pharmacol. 126(3): 746-50. (February 1999)]를 가짐을 발표하고 있다.Previous studies have shown that beta-raffonin has anticancer effects [Terai, Kaoru et al ., Cisplatin enhances the anticancer effect of beta - lapachone by upregulating NQO1 . , Anticancer Drugs , Nov, 01; 20 (10): 901-9 (2009); United States Patent Nos. 7,074,824, 6,962,944, 6,664,288, 7,361,691, WO 2003/11224], antitumor effect [HR Shah et al ., Beta - lapachone inhibits proliferation and induce apoptosis in retinoblastoma cell linesBeta - lapachone in retinoblastoma cell lines , Eye 22, 454-460 (March 2008); U.S. Patent Application Publication Nos. 2009/0226395 and 7,070,797], anti-inflammatory effects [Dong-Oh Moon et al ., Anti-inflammatory effects of β- lapachone in lipopolysaccharide - stimulated BV2 Microglia , International Immunopharmacology , Vol 7, Issue 4, 506-514, (April 2007)], antifungal effect [Shing-Hwa Liu et al ., Inhibition of inducible nitric oxide synthase by β-lapachone in rat alveolar macrophages and aorta , Br J Pharmacol . 126 (3): 746-50. (February 1999)].
그러나 상기한 연구속에서도 본 발명의 유효성분인 베타-라파콘의 피부 주름개선 효과에 관해서는 그 어떠한 연구도 없었다.However, no research has been conducted on the effect of beta-rapacon, which is an active ingredient of the present invention, on the wrinkles of the skin even in the above-mentioned studies.
본 발명자들은 베타-라파콘이 콜라겐 생성을 촉진하여 실제적으로 피부에 적용되는 경우 피부 주름 개선 효과를 나타냄을 확인함으로써 본 발명을 완성하였다.The inventors of the present invention have completed the present invention by confirming that beta-raffoncone promotes collagen production and actually exhibits an effect of improving skin wrinkles when applied to skin.
따라서, 본 발명은 베타-라파콘을 유효성분으로 포함하는 콜라겐 합성 촉진용 피부 외용제 조성물을 제공하는 것을 그 목적으로 한다.Accordingly, it is an object of the present invention to provide a composition for promoting collagen synthesis that contains beta-raffone as an active ingredient.
또한, 본 발명은 베타-라파콘을 유효성분으로 포함하는 주름 개선용 화장료 조성물을 제공하는 것을 다른 목적으로 한다.Another object of the present invention is to provide a cosmetic composition for improving wrinkles containing beta-raffone as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 베타-라파콘을 유효성분으로 포함하는 콜라겐 합성 촉진용 피부 외용제 조성물을 제공한다:In order to achieve the above object, the present invention provides a composition for promoting collagen synthesis, which comprises beta-raffone as an active ingredient represented by the following formula 1:
또한, 본 발명은 상기 화학식 1로 표시되는 베타-라파콘을 유효성분으로 포함하는 주름 개선용 화장료 조성물을 제공한다.The present invention also provides a cosmetic composition for improving wrinkles comprising the beta-rapacon represented by Formula 1 as an active ingredient.
본 발명에 따른 외용제 조성물 및 화장료 조성물은 피부 진피 층의 섬유아세포에 작용하여 콜라겐 생성을 촉진하고, 종래의 주름개선제인 레티놀에 비하여 낮은 농도에서 현저히 우수한 콜라겐 생성 촉진 효과를 나타내어 주름개선 효과가 각별할 뿐만 아니라, 제형 안정성이 우수하고 피부에 대한 부작용이 거의 없다.The composition for external application and cosmetic composition according to the present invention act on fibroblasts of skin dermal layer to promote collagen production and exhibit remarkably excellent collagen production promoting effect at a low concentration as compared with retinol as a conventional wrinkle remedy, In addition, it has excellent formulation stability and little side effects on the skin.
본 발명에서 제시하는 베타-라파콘은 하기 화학식 1로 표시되는 3,4-디하이드로-2,2-디메틸-2H-나프토(1,2-b)피란-5,6-디온(3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione) 화합물이다:The beta-raffone conferred by the present invention is 3,4-dihydro-2,2-dimethyl-2H-naphtho (1,2-b) pyran-5,6- 4-Dihydro-2,2-dimethyl-2H-naphtho (1,2-b) pyran-5,6-
[화학식 1][Chemical Formula 1]
상기 베타-라파콘은 CAS No.가 1707-32- 8 인 공지된 물질로서 천연 식물로부터 추출하거나 시판되는 것을 구입하여 사용할 수 있다.The beta-Rapa cones can be purchased that is a CAS No. 1707-32- 8 of known materials that are commercially available or extracted from natural plants.
천연 식물로부터 추출되는 베타-라파콘은 능소화과(Bignoniaceae), 마편초과(Verbenaceae), 프로테아과(Proteaceae), 콩과(Lequminosae), 사포타과(Sapotaceae), 현삼과(Scrophulariaceae), 아욱과(Malvaceae) 등의 식물에서 추출하여 얻어낼 수 있다. Beta extracted from natural plant-Rapa cone bignoniaceae (Bignoniaceae), verbenaceae (Verbenaceae), proteaceae (Proteaceae), leguminous (Lequminosae), sandpaper tagwa (Sapotaceae), Scrophulariaceae (Scrophulariaceae), Malvaceae (Malvaceae), etc. Of the plant.
일예로, 당업계 공지된 통상의 방법, 즉, 통상적인 용매를 사용하여, 통상적으로 이용되는 열수추출, 실온추출, 가온추출, 초음파추출, 초임계추출 등의 방법으로 제조될 수 있다. For example, it can be produced by a conventional method known in the art, that is, a conventional method such as hot water extraction, room temperature extraction, warming extraction, ultrasonic extraction, supercritical extraction and the like using a conventional solvent.
바람직하게는 물, 탄소수 1 내지 6의 저급 글리콜, 탄소수 1 내지 4의 저급알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 용매를 사용하여 추출한다. 가장 바람직하게는 1,3-부틸렌글리콜을 추출용매로 하여, 실온에서 초음파 추출기로 1 내지 12 시간 동안 추출한다. 상기 초음파 추출의 시간은 추출하고자 하는 시료의 양에 따라 달라질 수 있으며, 추출 결과물을 여과 또는 정제하는 과정을 거칠 수 있다. Is preferably extracted with a solvent selected from the group consisting of water, lower glycols having 1 to 6 carbon atoms, lower alcohols having 1 to 4 carbon atoms, and mixtures thereof. Most preferably, 1,3-butylene glycol is used as an extraction solvent and extracted with a sonicator at room temperature for 1 to 12 hours. The time of the ultrasonic extraction may be varied depending on the amount of the sample to be extracted, and the result of the extraction may be filtered or purified.
또한, 시판되는 베타-라파콘의 경우 구입 후 정제하여 사용한다. 이때 사용되는 정제방법은 이 분야에서 통상적으로 사용되는 방법이 가능하다. 각종 유기용매를 혼합하여 사용한 액-액 추출, 실리카겔이나 활성 알루미나 등의 각종 합성수지를 충진한 컬럼크로마토그래피 및 고속액체크로마토그래피(HPLC) 등의 정제방법이 가능하며, 위의 정제 방법에 한정된 것은 아니다.In the case of commercially available beta-rapacon, it is used after refining. The purification method used at this time can be a method commonly used in this field. Liquid chromatography using various organic solvents, column chromatography using various synthetic resins such as silica gel and activated alumina, and high performance liquid chromatography (HPLC), and the method is not limited to the above purification method .
본 발명에 따른 실험예 1에서 베타-라파콘의 콜라겐 합성 효과를 알아보기 위해 실험한 결과, 종래 콜라겐 생성 촉진용 물질로 많이 사용되는 레티놀에 비해서 베타-라파콘의 콜라겐 생합성 효과가 보다 우수함을 입증하였다.In order to examine the effect of collagen synthesis of beta-rapacon in Experimental Example 1 according to the present invention, it was proved that the collagen biosynthesis effect of beta-rapacon was superior to that of retinol, which is conventionally used as collagen production promoting substance Respectively.
이러한 결과를 통해 본 발명에서 제시하는 베타-라파콘은 피부 외용제 조성물 및 화장료 조성물로 적용이 가능하고, 이를 피부에 적용시 콜라겐 합성을 촉진함으로써, 피부 주름을 보다 완화시킬 수 있고 하고, 견고하며 탄력있게 유지해주는 효과를 얻을 수 있다.These results indicate that beta-raffone conceived in the present invention can be applied as a composition for external application for skin and a cosmetic composition, and can promote collagen synthesis when applied to the skin, thereby reducing skin wrinkles, The effect can be obtained.
베타-라파콘은 전체 외용제 조성물 중량 대비 0.00001∼10.0 중량%, 바람직하게는 0.001∼0.1 중량%를 포함할 수 있다. 만약, 상기 화합물의 함량이 상기 범위 미만일 경우 뚜렷한 효과를 기대할 수 없고, 반대로 상기 범위를 초과하는 경우 포함량의 증가에 비해 효과의 증가가 미치지 못하며 약간의 세포 독성을 야기할 수 있다.Beta-raffone may contain 0.00001 to 10.0% by weight, preferably 0.001 to 0.1% by weight, based on the weight of the total external preparation composition. If the content of the compound is less than the above range, a significant effect can not be expected. On the other hand, if the content exceeds the above range, the effect is not increased and an amount of cytotoxicity may be slightly increased.
상기 외용제 조성물은 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들어 바디 로션, 연고, 겔, 크림, 패취 또는 분무제의 제형을 갖는 외용제 조성물일 수 있다. 이때 각 제형의 외용제 조성물에 있어서, 상기한 베타-라파콘 이외의 다른 성분들은 기타 외용제의 제형 또는 사용목적 등에 따라 당업자가 적의 선정하여 배합할 수 있다.
The external preparation composition is not particularly limited in its formulation and may be, for example, an external preparation composition having a formulation of a body lotion, ointment, gel, cream, patch or spray. At this time, in the composition for external application for each formulation, components other than the above-mentioned beta-rapacon can be formulated by a person skilled in the art according to the formulation or purpose of use of the other external preparation.
특히, 본 발명에 따른 베타-라파콘은 콜라겐 합성 촉진 효과를 통해 이를 유효성분으로 포함하는 화장료 조성물로서 적용이 가능하다.In particular, the beta-rapacon according to the present invention can be applied as a cosmetic composition containing it as an active ingredient through promoting collagen synthesis.
본 발명에 따른 실험예 2에서 베타-라파콘을 포함하는 크림을 피부에 도포한 결과 높은 주름 개선 효과를 나타내고, 실험예 3에서 피부 자극을 측정한 결과 상기 화합물이 피부 자극을 유발하지 않음을 확인하였다.In Experimental Example 2 of the present invention, the cream containing beta-rapacon was applied to the skin to show a high wrinkle-reducing effect. In Experimental Example 3, skin irritation was measured and it was confirmed that the compound did not cause skin irritation Respectively.
베타-라파콘은 전체 화장료 조성물 중량 대비 0.00001∼10.0 중량%, 바람직하게는 0.001∼0.1 중량%를 포함할 수 있다. 만약, 베타-라파콘의 함량이 상기 범위 미만일 경우 뚜렷한 효과를 기대할 수 없고, 반대로 상기 범위를 초과하는 경우 포함량의 증가에 비해 효과의 증가가 미치지 못하며 약간의 세포 독성을 띈다.Beta-raffone may contain 0.00001-10.0 wt%, preferably 0.001-0.1 wt%, based on the total weight of the cosmetic composition. If the content of beta-rapacon is less than the above range, no remarkable effect can be expected. On the other hand, if the content exceeds the above range, the effect is not increased as compared with the content of beta-rapacon, and slight cytotoxicity is exhibited.
상기 화장료 조성물은 조성물은 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들어 화장수, 유액, 크림, 폼, 에센스, 세럼, 유연수, 유액, 파운데이션, 메이크업 베이스, 비누, 선 스크린크림 및 선 오일 등의 제형으로 제조할 수 있다. The composition of the cosmetic composition is not particularly limited in its formulation and may be in the form of a lotion such as a lotion, a milky lotion, a cream, a foam, an essence, a serum, a soft water, an emulsion, a foundation, a makeup base, a soap, ≪ / RTI >
또한 각 제형의 조성들은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 그 효과를 떨어트리지 않는 범위 내에서 비이온 계면활성제, 실리콘 폴리머, 체질안료, 향료, 방부제, 살균제, 산화 안정화제, 유기 용매, 이온성 또는 비이온성 증점제, 유연화제, 산화방지제, 자유 라디칼 파괴제, 불투명화제, 안정화제, 에몰리언트(emollient), 실리콘, α-히드록시산, 소포제, 보습제, 비타민, 곤충 기피제, 향료, 보존제, 계면활성제, 소염제, 물질 P 길항제, 충전제, 중합체, 추진제, 염기성화 또는 산성화제, 또는 착색제 등 공지의 화합물을 포함하여 제조된다. In addition, the compositions of each formulation may contain various bases and additives necessary for formulation of the formulation, and may contain a nonionic surfactant, a silicone polymer, an extender pigment, a flavoring, a preservative, a disinfectant , An oxidative stabilizer, an organic solvent, an ionic or nonionic thickener, a softening agent, an antioxidant, a free radical scavenger, an opacifying agent, a stabilizer, an emollient, a silicone, an a-hydroxy acid, a defoaming agent, , Insect repellents, perfumes, preservatives, surfactants, anti-inflammatory agents, substance P antagonists, fillers, polymers, propellants, basic or acidifying agents, or coloring agents.
본 발명의 화장품 조성물에 포함되는 성분은 유효 성분으로서의 베타-라파콘 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The ingredients contained in the cosmetic composition of the present invention include components commonly used in cosmetic compositions in addition to beta-raffone as an active ingredient, and include conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, , And a carrier.
본 발명의 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다. The composition of the present invention may be prepared into any of the formulations conventionally produced in the art and may be formulated into various forms such as solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, Oils, powder foundations, emulsion foundations, wax foundations and sprays, but are not limited thereto. More specifically, it can be manufactured in the form of a softening agent, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다. When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 상기 베타-라파콘은 콜라겐 및 엘라스틴 생합성 촉진 효과가 매우 우수하였고(실험예 1 참조), 피부 주름을 효과적으로 개선하고 탄력을 증진시켰으며 (실험예 2 참조), 인체피부에 자극이 거의 없으며(실험예 3 참조), 제형내 안정성이 우수한 것을 알 수 있다(실험예 4 참조).
The beta-rapacon of the present invention was excellent in promoting collagen and elastin biosynthesis (see Experimental Example 1), effectively improving skin wrinkles and improving elasticity (see Experimental Example 2) (See Experimental Example 3), indicating that the stability in the formulation is excellent (see Experimental Example 4).
[실시예][Example]
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 실험예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.
Hereinafter, preferred embodiments and experimental examples are provided to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples.
실험예Experimental Example 1: One: TypeType I I collagencollagen 생합성 촉진 효과 Promoting biosynthesis
본 발명에 따른 베타-라파콘의 콜라겐 합성효과를 알아보기 위해 시그마 알드리치사에서 구입하여 정제하여 사용하였다.In order to examine the effect of collagen synthesis of beta-rapacon according to the present invention, it was purchased from Sigma-Aldrich and used for purification.
사람의 정상 섬유아세포(human normal fibroblast)를 10%의 우태아 혈청이 함유된 DMEM 배지가 들어 있는 48-웰 마이크로 플레이트에 접종시키고(1x105세포/웰), 5% 농도(CO2)의 CO2 배양기에서 37℃로 24시간 배양하였다. 이때 사람의 정상 섬유아세포는 병원에서 신생아의 포경 수술 후 채취한 피부조직을 분리하여 사용하였다.Normal fibroblasts (normal human fibroblast) 10% of fetal bovine serum inoculated in a 48-well microplate containing DMEM medium and containing (1x10 5 cells / well) and the 5% concentration (CO 2) of the person CO 2 incubator at 37 < 0 > C for 24 hours. At this time, the human normal fibroblasts were separated from the skin tissue collected after circumcision of the newborn in the hospital.
베타-라파콘 및 레티놀이 적정 농도로 함유된 혈청이 들어있지 않은 DMEM 배지를 만들고, 이 배지로 교체하여 24시간 동안 배양한 후, 세포 배양액을 채취하였다. 타카라사(Takara Shuzo Co., Ltd. 일본국)의 콜라겐 단백질 측정키트와 바이오컬러사(Biocolor Co., Ltd. 영국)의 엘라스틴 단백질 측정 키트를 사용하여, 채취한 세포 배양액에서 생성된 프로콜라겐 타입 I의 C-펩타이드와 엘라스틴의 양을 측정함으로써 콜라겐 및 엘라스틴 생성 촉진 정도를 확인하였으며, 그 결과를 하기 표 1에 나타내었다.DMEM medium containing no serum containing beta-rapacon and retinol at an appropriate concentration was prepared, cultured for 24 hours by replacing with this medium, and cell culture medium was collected. Using the collagen protein measurement kit of Takara Shuzo Co., Ltd. (Japan) and the elastin protein measurement kit of Biocolor Co., Ltd. (United Kingdom), the procollagen type I of C-peptide and elastin were measured to confirm the degree of promoting collagen and elastin production. The results are shown in Table 1 below.
(상대%)Cell viability
(opponent%)
상기 표 1을 참조하면, 본 발명에 따른 베타-라파콘을 적용하였을 때 레티놀과 동등 이상의 우수한 콜라겐 및 엘라스틴 생성 효과가 나타남을 알 수 있었다. 특히, 베타-라파콘의 농도가 0.1 ppm인 경우 콜라겐 및 엘라스틴 생성율이 레티놀과 비교하여 월등히 향상되는 결과를 확인하였다.
Referring to Table 1 above, when the beta-rapacon according to the present invention was applied, excellent collagen and elastin-producing effects equal to or more than retinol were obtained. Particularly, when the concentration of beta-rapacon was 0.1 ppm, the production rate of collagen and elastin was remarkably improved compared with that of retinol.
실험예Experimental Example 2: 주름개선 효과 2: Wrinkle improvement effect
본 발명에 따른 베타-라파콘의 주름 개선 효과를 확인하기 위해 크림 제형으로 제조 후 관능 시험을 수행하였다.In order to confirm the wrinkle-improving effect of the beta-raffon cone according to the present invention, a sensory test was carried out after preparation with a cream formulation.
잔주름 및 굵은 주름을 지닌 30∼60세 성인 여성 20명을 대상으로의 하기 제형예 3의 조성으로 제조된 크림을 8주 동안 1일 2회 안면 양쪽 눈가에 각각 도포하였다. Derma Top-blue(Breuckmann Corporation, 독일국)를 이용하여 제품 사용 전과 사용 후의 피부 주름 변화를 다양한 파라미터로 측정하였고, 얻어진 결과를 하기 표에 나타내었다. Twenty women aged 30 to 60 years with fine wrinkles and thick wrinkles were applied cream of the composition of Formulation Example 3 on both sides of the face twice a day for 8 weeks. Derma Top-blue (Breuckmann Corporation, Germany) was used to measure changes in skin wrinkles before and after product use with various parameters, and the obtained results are shown in the following table.
Cutometer(Courage-Khazaka electronic GmbH, 독일국)를 이용하여 제품 사용전과 사용후의 피부 탄력 변화를 측정하였고, 얻어진 결과를 하기 표 2 및 3에 나타내었다.The change in skin elasticity before and after use of the product was measured using a cutometer (Courage-Khazaka electronic GmbH, Germany). The obtained results are shown in Tables 2 and 3 below.
이때 비교예로서 사용한 레티놀 함유 크림은 하기 제형예 3의 조성에서 베타-라파콘 0.0001% 대신 레티놀 2500IU(750ug/g, 0.075%, 식약청 고시 함량)로 대체한 것이다.At this time, the retinol-containing cream used as a comparative example was replaced with 2500 IU (750 ug / g, 0.075%, KFDA) of retinol instead of 0.0001% of beta-raffone in the composition of Formulation 3 below.
<3D 거칠기도 인자(roughness parameters)>≪ 3D roughness parameters >
- Spt : 주름의 굴곡중 최고 높이와 최저 계곡의 거리- Spt: the maximum height of the bend of the wrinkle and the distance of the lowest valley
- Spa : 굴곡의 높은 곳과 낮은 곳의 평균거리- Spa: Average distance between high and low bends
- Sdev : 분석 면적을 1로 하였을 때 주름 부분을 평편하게 폈을 때의 면적- Sdev: Area when the wrinkles are flattened when the analysis area is 1
- Sptm : 피크와 계곡의 평균거리(최대 피크 5개의 평균과 최저 계곡 5개의 평균의 합)- Sptm: Average distance between peaks and valleys (sum of 5 peaks maximum and 5 lowest peaks)
Example (Beta-Raffoon Cone-containing Cream)
상기 표 2 및 표 3을 참조하면, 본 발명에 따른 베타-라파콘을 포함하는 크림을 피부에 적용하는 경우, 기존 레티놀 함유 크림과 비교하여, 4~8주 사용 후 피부 주름 개선, 및 탄력증가 효능이 우수함을 알 수 있다.
Table 2 and Table 3 show that when the cream containing beta-rapacon according to the present invention is applied to the skin, compared to the existing retinol-containing cream, the skin wrinkle improvement and the elasticity increase after 4 to 8 weeks of use It can be seen that the efficacy is excellent.
실험예Experimental Example 3: 피부 자극 3: Skin irritation
본 발명에 따른 베타-라파콘의 피부 자극의 여부를 알아보기 위해 하기와 같은 평가를 수행하였다. The following evaluation was conducted to examine whether or not the skin irritation of the beta-rapacon according to the present invention is present.
이때 비교예로서 사용한 레티놀 함유 크림은 하기 제형예 3의 조성에서 베타-라파콘 0.0001% 대신 레티놀 2500IU로 대체한 것이다.At this time, the retinol-containing cream used as a comparative example was replaced with 2500 IU of retinol instead of 0.0001% of beta-raffone in the composition of Formulation Example 3 below.
1) 인체 피부 첩포시험1) Human skin patch test
과거력상 피부자극에 과민반응을 보인 적이 없으며, 현재 피부병 내지 피부 알러지 증상이 없는 20∼30대 여성 20명을 대상으로 객관적 피부 자극도를 측정하였다.Objective skin irritation was measured in 20 women in their 20s and 30s who had never been hypersensitive to skin irritation due to a history of skin disease or skin allergy.
시험부위를 70% 에탄올로 닦아낸 뒤 건조시켰다. 준비된 시험물질을 15 ㎍씩 핀 챔버(Finn chamber, 100±10, EPITEST, 핀란드국) 내에 적하시킨 후 시험대상자의 전박(forearm) 안쪽 부위에 밀폐 첩포하였다. 24시간 동안 첩포하고 첩포를 제거한 후 표시펜으로 시험부위를 표시하였다. 각각 1시간 그리고 24시간 후(첩포 제거 후 1시간, 24시간 후 = 첩포 부착 포함 24시간, 48시간)에 확대경(8MC-150, DAZOR, 미합중국)을 이용하여 시험 부위를 관찰하여 홍반 및 부종 유무를 관찰하였다.The test area was wiped with 70% ethanol and then dried. 15 μg of the prepared test substance was dripped into a Finn chamber (100 ± 10, EPITEST, Finland) with a hermetic seal on the inside of the forearm of the test subject. After 24 hours of exposure, the patches were removed and marked with the marking pen. (8MC-150, DAZOR, United States of America) at 1 hour and 24 hours (24 hours, 48 hours, including 1 hour and 24 hours after removal of the patches) Respectively.
이때 피부반응은 국제접촉피부염연구회(ICDRG: International Contact Dermatitis Research Group )의 규정에 따라 판정하였으며(표 4), 하기 수학식 1에 의하여 평균 피부 반응도를 계산하였고, 얻어진 결과를 표 5에 나타내었다.The skin reaction was judged according to the rules of the International Contact Dermatitis Research Group (ICDRG) (Table 4), and the average skin response was calculated by the following formula (1).
상기 표 5를 참조하면, 본 발명에 따른 베타-라파콘을 함유한 크림의 경우 레티놀 크림과 비교하여 피부 반응도가 약 11배 이상 낮아 피부 자극이 현저히 적음을 알 수 있다.
Referring to Table 5, it can be seen that the cream containing the beta-rapacon according to the present invention has a skin irritation rate significantly lower than that of the retinol cream because the skin response is about 11 times lower.
2) 자극감 시험2) Stimulation test
과거력상 피부자극에 과민반응을 보인 적이 없으며, 현재 피부병 내지 피부 알러지 증상이 없는 20∼40대 여성 20명을 대상으로 주관적 피부 자극도를 측정하였다.Subjective skin irritation was measured in 20 women in their 20s and 40s who had never been hypersensitive to skin irritation due to a history of skin disease or skin allergy.
증기 발생기(Steam Generator)를 사용하여 15분간 충분히 스웨팅(Sweating) 시킨 후, 얼굴 양쪽에 화장료 조성물을 코 주위 및 뺨을 중심으로 강하게 비빈 다음, 얼굴에 나타나는 주관적 피부반응을 10분 동안 관찰하였다. 단, 건선(Psoriasis), 습진(Eczema), 기타 피부병변 보유자나 임신, 수유부 또는 피임제, 항히스타민제 등을 복용하고 있는 사람은 본 시험에서 제외하였다.After thoroughly sweating for 15 minutes using a steam generator, the cosmetic composition on both sides of the face was vigorously shaken around the nose and cheek, and the subjective skin reaction on the face was observed for 10 minutes. However, people taking psoriasis, eczema, other skin lesions, pregnant, lactating or contraceptive, and antihistamines are excluded from this test.
화장료 적용 후 자극 반응이 나타나는 시간에 따라 1분 단위로 점수를 기재하고 하기 수학식 2에 의하여 평균 피부 반응도를 계산하였고, 얻어진 결과를 하기 표 6 및 표 7에 나타내었다.The average skin response was calculated by the following formula (2) and the results are shown in Tables 6 and 7 below.
상기 표 6 및 표 7을 참조하면, 본 발명에 따른 베타-라파콘을 함유한 크림의 경우 종래 레티놀 크림에 비해 피부 자극이 약 9배 가량 크게 낮음을 알 수 있다.
Referring to Tables 6 and 7, it can be seen that the cream containing the beta-rapacon according to the present invention has a skin irritation about 9 times as low as that of the conventional retinol cream.
실험예Experimental Example 4: 4: 화장료Cosmetics 제형의 안정성 시험 Stability test of formulation
본 발명에 따른 베타-라파콘의 안정성 알아보기 위해 하기와 같은 평가를 수행하였다. To evaluate the stability of beta-rapacon according to the present invention, the following evaluation was conducted.
이때 비교예로서 사용한 레티놀 함유 크림은 하기 제형예 3의 조성에서 베타-라파콘 0.0001% 대신 레티놀 2500IU로 대체한 것이다.At this time, the retinol-containing cream used as a comparative example was replaced with 2500 IU of retinol instead of 0.0001% of beta-raffone in the composition of Formulation Example 3 below.
베타-라파콘을 함유한 크림과 레티놀을 함유한 크림을 불투명 초자 용기에 담아 45℃로 일정하게 유지되는 항온조에서 1~4주 동안 보관하고, 불투명 초자 용기에 담아 4℃로 일정하게 유지되고 완전히 차광된 냉장고 내에서 1~4주 동안 보관한 후 고압액체크로마토그래피(HPLC)방법으로 정량하였다.The cream containing beta-rapacon and the cream containing retinol were placed in an opaque glazed container and kept in a thermostat maintained at 45 ° C for 1 to 4 weeks. After storage for 1 to 4 weeks in a shaded refrigerator, it was quantified by high pressure liquid chromatography (HPLC).
(레티놀 함유 크림)Comparative Example
(Retinol-containing cream)
(베타-라파콘 함유 크림)Example
(Beta-Raffone Concentrated Cream)
상기 표 8을 참조하면, 본 발명에 따른 베타-라파콘을 함유한 크림의 경우, 종래 레티놀 크림과 비교하여 제형 안정성이 월등히 우수한 것으로 나타났다.
Referring to Table 8, in the case of the cream containing the beta-raffone cone according to the present invention, the formulation stability was remarkably superior to the conventional retinol cream.
이하, 본 발명의 이해를 돕기 위하여 바람직한 제형예를 제시한다. 그러나 하기의 제형예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 제형예에 의해 본 발명의 내용이 한정되는 것은 아니다.
Hereinafter, a preferred formulation example is provided to facilitate understanding of the present invention. However, the following formulation examples are provided only for a better understanding of the present invention, and the present invention is not limited by the formulation examples.
제형예Formulation Example 1: 유연화장수 (스킨로션) 1: Softened longevity (skin lotion)
하기의 표 9와 같이 베타-라파콘을 함유하는 유연화장수를 통상의 방법에 따라 제조하였다.The softening water containing beta-raffone cone was prepared according to a conventional method as shown in Table 9 below.
제형예Formulation Example 2: 수렴화장수 2: convergent lotion
하기의 표 10과 같이 베타-라파콘을 함유하는 수렴화장수를 통상의 방법에 따라 제조하였다.Convergent lotion containing beta-rapacon was prepared according to the conventional method as shown in Table 10 below.
제형예Formulation Example 3: 영양화장수 3: Nourishing lotion
하기의 표 11과 같이 베타-라파콘을 함유하는 영양화장수를 통상의 방법에 따라 제조하였다.A nutritional lotion containing beta-rapacon was prepared according to a conventional method as shown in Table 11 below.
제형예Formulation Example 4: 영양크림 4: Nourishing cream
하기의 표 12와 같이 베타-라파콘을 함유하는 영양크림을 통상의 방법에 따라 제조하였다.A nutritional cream containing beta-rapacon was prepared according to the conventional method as shown in Table 12 below.
제형예Formulation Example 5 : 5: 맛사지Massage 크림 cream
하기의 표 13과 같이 베타-라파콘을 함유하는 맛사지 크림을 통상의 방법에 따라 제조하였다.Massage cream containing beta-rapacon was prepared according to the usual method as shown in Table 13 below.
제형예Formulation Example 6 : 에센스 6: Essence
하기의 표 14와 같이 베타-라파콘을 함유하는 에센스를 통상의 방법에 따라 제조하였다.Essences containing beta-rapacon were prepared according to the conventional method as shown in Table 14 below.
제형예Formulation Example 7: 팩 7: Pack
하기의 표 15와 같이 베타-라파콘을 함유하는 팩을 통상의 방법에 따라 제조하였다.Packs containing beta-rapacon as shown in Table 15 below were prepared according to a conventional method.
제형예Formulation Example 8: 연고 8: Ointment
하기 표 16과 같이 베타-라파콘을 함유하는 연고를 통상의 방법에 따라 제조하였다.Ointment containing beta-rapacon was prepared according to the conventional method as shown in Table 16 below.
Claims (7)
[화학식 1]
[Chemical Formula 1]
[화학식 1]
[Chemical Formula 1]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100035204A KR101528265B1 (en) | 2010-04-16 | 2010-04-16 | Cosmetic Composition for Reducing Skin Wrinkle Comprising beta-Lapachone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100035204A KR101528265B1 (en) | 2010-04-16 | 2010-04-16 | Cosmetic Composition for Reducing Skin Wrinkle Comprising beta-Lapachone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110115722A KR20110115722A (en) | 2011-10-24 |
| KR101528265B1 true KR101528265B1 (en) | 2015-06-11 |
Family
ID=45030267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100035204A KR101528265B1 (en) | 2010-04-16 | 2010-04-16 | Cosmetic Composition for Reducing Skin Wrinkle Comprising beta-Lapachone |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101528265B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190081154A (en) | 2017-12-29 | 2019-07-09 | 서강대학교산학협력단 | Poly(N-isopropylacrylamide)-co-acrylacid encapsulating beta-Lapachone and method for preparing the same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040054667A (en) * | 2001-07-31 | 2004-06-25 | 아르퀼 인코포레이티드 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| JP2007512378A (en) * | 2003-11-26 | 2007-05-17 | アークル インコーポレイテッド | Use of β-lapachone to protect against radiation damage |
| JP2007523193A (en) * | 2004-02-20 | 2007-08-16 | アークル・インコーポレーテツド | Use of β-lapachone for the treatment of pancreatic cancer |
| JP2009280597A (en) * | 2001-08-29 | 2009-12-03 | Univ Of British Columbia | Use of fucan in treating psoriasis |
-
2010
- 2010-04-16 KR KR1020100035204A patent/KR101528265B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040054667A (en) * | 2001-07-31 | 2004-06-25 | 아르퀼 인코포레이티드 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| JP2009280597A (en) * | 2001-08-29 | 2009-12-03 | Univ Of British Columbia | Use of fucan in treating psoriasis |
| JP2007512378A (en) * | 2003-11-26 | 2007-05-17 | アークル インコーポレイテッド | Use of β-lapachone to protect against radiation damage |
| JP2007523193A (en) * | 2004-02-20 | 2007-08-16 | アークル・インコーポレーテツド | Use of β-lapachone for the treatment of pancreatic cancer |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190081154A (en) | 2017-12-29 | 2019-07-09 | 서강대학교산학협력단 | Poly(N-isopropylacrylamide)-co-acrylacid encapsulating beta-Lapachone and method for preparing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110115722A (en) | 2011-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100501399B1 (en) | Cosmetic Compostion for Preventing Skin Aging Comprising Plant Extract as Oriental Medicine Stabilized in Nanoliposome | |
| KR101020536B1 (en) | Moisturizing cosmetic composition containing extract of Sanguisorba officinalis and method of producing the same | |
| KR101668029B1 (en) | Cosmetic Composition for Reducing Skin Wrinkle Comprising Lapachol | |
| KR20150078868A (en) | Cosmetic composition containing ginsenoside Rd, Rb2 and Bambusae Caulis in Taeniam extracts | |
| KR101508694B1 (en) | Cosmetic Composition for the Skin Whitening Comprising the Lapachol | |
| KR100638053B1 (en) | Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient | |
| KR20190021083A (en) | Cosmetic composition comprising extract of Alpinia officinarum Hance as active ingredient | |
| KR101528265B1 (en) | Cosmetic Composition for Reducing Skin Wrinkle Comprising beta-Lapachone | |
| KR101620820B1 (en) | Cosmetic Composition for Improving Skin Appearances Comprising Ginsenoside as Active Ingredient | |
| KR102541771B1 (en) | Cosmetic Composition For Moisturizing Skin Comprising Mixed Extracts of Chaenomeles sinensis fruit, Diospyros kaki leaf, Cinnamomum cassia bark, Artemisia princeps leaf, Chrysanthellum indicum and Camellia sinensis leaf as Active Ingredient | |
| KR20110030187A (en) | (a cosmetic composition for skin miosture containing mixing extract of sparassis crispa, agaricus blazeii and polyporus umbellatus | |
| KR20070008270A (en) | Cosmetic composition for preventing skin aging comprising radix glycyrrhizae, phellodendri cortex, radix cynanchi wilfordii and cortex mori extract stabilized in nanoliposome | |
| KR101897570B1 (en) | Composition for anti-wrinkle comprising handroanthus impetiginosus extract and method for preparing the extract | |
| KR20110094859A (en) | Composition for promoting collagen synthesis having kava extract | |
| KR100878026B1 (en) | The cosmetic composition for moisturizing of skin containing the thymus quinquecostatus extracts stabilized with nanoliposome | |
| KR20070111025A (en) | Anti-wrinkle cosmetic compositions comprising the extract of phaseolus radiatus as active ingredient | |
| JP2008247787A (en) | External preparation for skin | |
| KR20090055957A (en) | Cosmetic composition for skin moisturizing comprising the extract of orostachys japonicus as active ingredient | |
| KR100747502B1 (en) | An anti-irritation complex for skin, and a cosmetic composition containing the same | |
| KR102048713B1 (en) | cosmetics containing boswellic acid | |
| KR101460900B1 (en) | Cosmetic composition for skin whitening, regeneration or moisturizing comprising epifriedelanol | |
| KR102202210B1 (en) | Moisturizing cosmetic composition comprising nutmeg extract, hyaluronic acid and sericin | |
| KR101454515B1 (en) | Composition for improving skin conditions comprising veratric acid or pharmaceutically acceptable salt thereof as an active ingredient | |
| KR20180096094A (en) | A composition for improving skin wrinkle comprising Cosmos bipinnatus extract | |
| KR20010057429A (en) | Skin care composition containing Ursolic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20180328 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20190326 Year of fee payment: 5 |